Literature DB >> 12668986

Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis.

Giovanni Musso1, Roberto Gambino, Franco De Michieli, Maurizio Cassader, Mario Rizzetto, Marilena Durazzo, Emanuela Fagà, Barbara Silli, Gianfranco Pagano.   

Abstract

The relations of dietary habits to insulin sensitivity and postprandial triglyceride metabolism were evaluated in 25 patients with nonalcoholic steatohepatitis (NASH) and 25 age-, body mass index (BMI)-, and gender-matched healthy controls. After a 7-day alimentary record, they underwent a standard oral glucose tolerance test (OGTT), and the insulin sensitivity index (ISI) was calculated from the OGTT; an oral fat load test was also performed in 15 patients and 15 controls. The dietary intake of NASH patients was richer in saturated fat (13.7% +/- 3.1% vs. 10.0% +/- 2.1% total kcal, respectively, P =.0001) and in cholesterol (506 +/- 108 vs. 405 +/- 111 mg/d, respectively, P =.002) and was poorer in polyunsaturated fat (10.0% +/- 3.5% vs. 14.5% +/- 4.0% total fat, respectively, P =.0001), fiber (12.9 +/- 4.1 vs. 23.2 +/- 7.8 g/d, respectively, P =.000), and antioxidant vitamins C (84.3 +/- 43.1 vs. 144.2 +/- 63.1 mg/d, respectively, P =.0001) and E (5.4 +/- 1.9 vs. 8.7 +/- 2.9 mg/d, respectively, P =.0001). The ISI was significantly lower in NASH patients than in controls. Postprandial total and very low density lipoproteins triglyceride at +4 hours and +6 hours, triglyceride area under the curve, and incremental triglyceride area under the curve were higher in NASH compared with controls. Saturated fat intake correlated with ISI, with the different features of the metabolic syndrome, and with the postprandial rise of triglyceride. Postprandial apolipoprotein (Apo) B48 and ApoB100 responses in NASH were flat and strikingly dissociated from the triglyceride response, suggesting a defect in ApoB secretion. In conclusion, dietary habits may promote steatohepatitis directly by modulating hepatic triglyceride accumulation and antioxidant activity as well as indirectly by affecting insulin sensitivity and postprandial triglyceride metabolism. Our findings provide further rationale for more specific alimentary interventions, particularly in nonobese, nondiabetic normolipidemic NASH patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668986     DOI: 10.1053/jhep.2003.50132

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  217 in total

1.  Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat.

Authors:  Takashi Moriya; Kazuya Kitamori; Hisao Naito; Yukie Yanagiba; Yuki Ito; Nozomi Yamagishi; Hazuki Tamada; Xiaofang Jia; Satoru Tsuchikura; Katsumi Ikeda; Yukio Yamori; Tamie Nakajima
Journal:  Environ Health Prev Med       Date:  2012-03-11       Impact factor: 3.674

2.  Plasma free myristic acid proportion is a predictor of nonalcoholic steatohepatitis.

Authors:  Kengo Tomita; Toshiaki Teratani; Hirokazu Yokoyama; Takahiro Suzuki; Rie Irie; Hirotoshi Ebinuma; Hidetsugu Saito; Ryota Hokari; Soichiro Miura; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2011-04-23       Impact factor: 3.199

3.  Fatty liver disease in children: eat now pay later.

Authors:  Ruth M L De Bruyne; Emer Fitzpatrick; Anil Dhawan
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

4.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

Review 5.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 6.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 8.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

10.  Nutritional assessments of patients with non-alcoholic fatty liver disease.

Authors:  Chin Hee Kim; Jillian B Kallman; Chunhong Bai; Lisa Pawloski; Constance Gewa; Aimal Arsalla; Mary Ellen Sabatella; Zobair M Younossi
Journal:  Obes Surg       Date:  2008-06-17       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.